CWBR

CohBar, Inc.

0.68 USD
-0.10 (-12.82%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

CohBar, Inc. stock is down -10.53% since 30 days ago. The next earnings date is Jun 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 June’s closed higher than May.

About CohBar, Inc.

The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for NASH and obesity.